NiaVasc 750 by Xymogen
NiaVasc 750 is a blood health supplement designed by Xymogen, based mainly on Niacin, also called vitamin B3.* Thanks to this, NiaVasc 750 may provide you with a wide range of potential health benefits, such as reduced blood pressure, improved skin health, or even a slight support of your brain health.* This makes it a versatile health support product that works great for your overall health and wellness.*
Who Should Consider NiaVasc 750 by Xymogen?
NiaVasc 750 may support your health if you:
- do not consume sufficient amounts of vitamin B3 (Niacin) in your diet*
- experience problems with blood pressure*
- are an aging individual seeking overall health support*
NiaVasc 750 —Potential Effects
NiaVasc 750 may support your:
- overall blood health*
- blood pressure*
- maintenance of healthy blood lipids*
- normal carotid intima-media thickness (CIMT)*
Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. Book a FREE product consultation to learn more about NiaVasc 750 by Xymogen.
Recommendation:
Xymogen suggests taking one tablet one to two times daily with food, or as directed by your healthcare practitioner.
Serving Size: 1 Tablet
Servings Per Container: 60 or 120
Amount Per Serving:
Niacin 750 mg
Other Ingredients: Vegetable waxes (rice bran and/or carnauba), stearic acid, magnesium stearate, and silica.
Does Not Contain: Wheat, gluten, corn, yeast, soy, animal or dairy products, fish, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, or artificial preservatives.
Caution: Take under ongoing supervision with regular monitoring of blood chemistry, especially liver function. Do not take if you are pregnant or lactating.
Consult your healthcare practitioner prior to use. Individuals taking medication should discuss potential interactions with their healthcare practitioner. Do not use if tamper seal is damaged.
Storage: Keep closed in a cool, dry place out of reach of children.
LEGAL NOTICE: Xymogen's Exclusive Professional Formulas are available through select licensed health care professionals. The Internet Sale and Discounting of XYMOGEN formulas are strictly prohibited. covenanthealthproducts.com makes XYMOGEN formulas available only to patients of our clinic. If you are a patient of covenanthealthproducts.com, you may inquire about XYMOGEN by calling (800) 627-6518
*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Click here to view Product Info Sheet
References:
- Parsons, W. B., Jr., Achor, R. W., Berge, K. G., et al. (1956). Changes in concentration of blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: Preliminary observations. Mayo Clinic Proceedings, 31(13), 377–390. [PMID: 13336128]
- Kannel, W. B. (1978). Recent findings from the Framingham study—I. Medical Times, 106(4), 23–27. [PMID: 642745]
- Hulley, S. B. (1988). The US National Cholesterol Education Program: Adult treatment guidelines. Drugs, 36(Suppl 3), 100–104. [PMID: 3254822]
- Morgan, J. M., Carey, C. M., Lincoff, A., et al. (2004). The effects of niacin on lipoprotein subclass distribution. Preventive Cardiology, 7(4), 182–187; quiz 188. [PMID: 8424822]
- Holland, R. E., Rahman, K., Morris, A. I., et al. (1993). Effect of niacin on biliary lipid output in the rat. Biochemical Pharmacology, 45(1), 43–49. [PMID: 8424822]
- Niacin. (n.d.). Retrieved August 19, 2010, from Natural Standard
- Taylor, A. J., Sullenberger, L. E., Lee, H. J., et al. (2004). Biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation, 110(23), 3512–3517. [PMID: 15537681]
- Villines, T. C., Stanek, E. J., Devine, P. J., et al. (2010). The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration. Journal of the American College of Cardiology, 55(24), 2721–2767. [PMID: 20399059]